A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria:

* Histologically or cytologically documented locally advanced or metastatic solid tumors for which standard therapies either do not exist or have proven ineffective or intolerable
* Evaluable disease or disease measurable per Response Evaluation Criteria in Solid Tumors (RECIST)
* Life expectancy \>/= 12 weeks
* Adequate hematologic and end organ function

Exclusion Criteria:

* History of prior significant toxicity from another MEK pathway inhibitor requiring discontinuation of treatment
* History of prior significant toxicity from another phosphoinositide 3-kinase (PI3K) or Akt pathway or mammalian target of rapamycin (mTOR) inhibitor requiring discontinuation of treatment
* Anti-cancer therapy within 28 days prior to first dose of study drug, except as stated in protocol
* History of type I or type II diabetes mellitus requiring insulin
* Current severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary, or metabolic disease)
* Clinically significant history of liver disease, current alcohol abuse, or current known active infection with HIV, hepatitis B or hepatitis C virus
* Active autoimmune disease
* Pregnant or lactating women
* Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms
* History of glaucoma
* History of retinal vein occlusion